Shalby
SHALBY NSE
Shalby
HealthcareNSE: SHALBY BSE: 540797 Healthcare Services
Key Fundamentals
MicrocapHospitalsHealthcare ServicesMarket Cap
₹1,554 Cr
Volatility
Low Risk
P/E Ratio
39.77
EBITDA
₹170 Cr
Return on Equity
3.45%
Debt to Equity
0.59
Book Value
₹93.11
EPS
₹7.22
52W High
₹274.7
52W Low
₹125.82
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company's working capital requirements have reduced from 32.0 days to 21.7 days
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 3.11% over last 3 years.
- Dividend payout has been low at 5.11% of profits over last 3 years
Growth Rate
Revenue Growth
4.81% lower than
3Y
Net Income Growth
—
Cash Flow Change
99.77% higher than
3Y
ROE
—
ROCE
4.1% higher than
3Y
EBITDA Margin (Avg.)
0.97% higher than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 235 | 238 | 216 | 244 | 279 | 268 | 276 | 265 | 296 | 285 | 272 | 287 | 331 |
| Expenses | 192 | 185 | 174 | 205 | 234 | 235 | 242 | 244 | 255 | 244 | 242 | 258 | 290 |
| Operating Profit | 43 | 53 | 42 | 39 | 45 | 33 | 34 | 21 | 42 | 42 | 30 | 29 | 42 |
| OPM % | 18% | 22% | 20% | 16% | 16% | 12% | 12% | 8% | 14% | 15% | 11% | 10% | 13% |
| Other Income | 5 | 5 | 5 | 5 | 10 | 7 | 5 | 5 | 7 | 4 | 7 | 8 | 7 |
| Interest | 3 | 3 | 4 | 6 | 8 | 9 | 11 | 11 | 9 | 10 | 11 | 9 | 11 |
| Depreciation | 12 | 12 | 12 | 16 | 16 | 17 | 16 | 16 | 17 | 17 | 18 | 18 | 19 |
| PBT | 33 | 43 | 31 | 22 | 30 | 14 | 12 | -1 | 23 | 19 | 9 | 10 | 20 |
| Tax % | 37% | 35% | 38% | 26% | 52% | 83% | 124% | 1547% | 66% | 62% | 86% | -92% | 47% |
| Net Profit | 21 | 28 | 19 | 16 | 15 | 2 | -3 | -12 | 8 | 7 | 1 | 18 | 10 |
| EPS in Rs | 1.93 | 2.55 | 1.77 | 1.54 | 1.45 | 0.31 | -0.17 | -1.02 | 0.83 | 0.78 | 0.16 | 1.7 | 1 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 275 | 290 | 324 | 378 | 462 | 487 | 431 | 699 | 805 | 934 | 1,087 | 1,141 | 1,176 |
| Expenses | 207 | 235 | 252 | 299 | 379 | 404 | 342 | 577 | 667 | 755 | 952 | 996 | 1,033 |
| Operating Profit | 68 | 56 | 71 | 79 | 83 | 83 | 89 | 122 | 138 | 179 | 135 | 145 | 143 |
| OPM % | 25% | 19% | 22% | 21% | 18% | 17% | 21% | 17% | 17% | 19% | 12% | 13% | 12% |
| Other Income | 2 | 2 | 7 | 10 | 9 | 17 | 8 | 8 | 22 | 19 | 28 | 27 | 27 |
| Interest | 5 | 10 | 11 | 12 | 9 | 7 | 5 | 8 | 11 | 18 | 41 | 41 | 40 |
| Depreciation | 21 | 11 | 17 | 23 | 33 | 36 | 37 | 43 | 48 | 52 | 66 | 70 | 72 |
| PBT | 43 | 36 | 50 | 54 | 50 | 57 | 55 | 79 | 102 | 128 | 56 | 61 | 58 |
| Tax % | 43% | -1% | 43% | 27% | 37% | 51% | 23% | 32% | 34% | 35% | 97% | 43% | — |
| Net Profit | 25 | 36 | 29 | 39 | 32 | 28 | 42 | 54 | 68 | 84 | 2 | 35 | 38 |
| EPS in Rs | 7.36 | 4.3 | 3.4 | 3.65 | 2.93 | 2.55 | 3.93 | 5.01 | 6.27 | 7.78 | 0.58 | 3.46 | 3.64 |
| Div. Payout % | 0% | 0% | 0% | 0% | 17% | 20% | 25% | 20% | 19% | 15% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 35 | 87 | 87 | 108 | 108 | 108 | 108 | 108 | 107 | 107 | 107 | 108 |
| Reserves | 133 | 117 | 164 | 643 | 672 | 691 | 727 | 768 | 820 | 893 | 885 | 898 |
| Borrowings | 98 | 224 | 328 | 114 | 71 | 62 | 44 | 155 | 180 | 378 | 476 | 595 |
| Other Liabilities | 85 | 75 | 99 | 96 | 89 | 105 | 118 | 162 | 173 | 231 | 241 | 248 |
| Total Liabilities | 351 | 504 | 679 | 961 | 939 | 967 | 997 | 1,194 | 1,281 | 1,609 | 1,709 | 1,848 |
| Fixed Assets | 175 | 319 | 323 | 650 | 692 | 672 | 660 | 675 | 685 | 966 | 955 | 1,046 |
| CWIP | 91 | 82 | 221 | 47 | 3 | 6 | 8 | 6 | 11 | 15 | 22 | 19 |
| Investments | 0 | 0 | 0 | 0 | 11 | 28 | 16 | 25 | 146 | 81 | 95 | 62 |
| Other Assets | 85 | 102 | 134 | 264 | 233 | 260 | 314 | 488 | 440 | 547 | 637 | 721 |
| Total Assets | 351 | 504 | 679 | 961 | 939 | 967 | 997 | 1,194 | 1,281 | 1,609 | 1,709 | 1,848 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | — | — | 60 | 14 | 43 | 55 | 79 | 19 | 68 | 20 | -4 | 0 |
| Investing | — | — | -153 | -236 | 1 | -31 | -51 | -60 | -61 | 146 | -36 | -97 |
| Financing | — | — | 96 | 222 | -51 | -22 | -30 | 90 | -50 | -151 | 48 | 84 |
| Net Cash Flow | — | — | 3 | 0 | -6 | 3 | -2 | 49 | -43 | 15 | 8 | -13 |
| Free Cash Flow | — | — | -98 | -124 | 12 | 244 | 58 | -56 | 50 | -26 | -74 | -145 |
| CFO/OP | — | — | 99 | 34 | 63 | 91 | 99 | 34 | 70 | 22 | 7 | 27 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 29 | 40 | 38 | 49 | 64 | 71 | 80 | 53 | 48 | 57 | 59 | 73 |
| Inventory Days | — | — | 77 | 113 | 119 | 105 | 242 | 1,063 | 1,152 | 1,361 | 1,033 | 928 |
| Days Payable | — | — | 395 | 462 | 522 | 415 | 606 | 621 | 546 | 744 | 377 | 310 |
| Cash Conversion Cycle | 29 | 40 | -280 | -299 | -339 | -239 | -283 | 495 | 654 | 673 | 715 | 692 |
| Working Capital Days | -46 | -26 | -64 | -18 | 57 | 70 | 77 | 75 | 75 | 48 | 26 | 22 |
| ROCE % | 22% | 13% | 12% | 9% | 7% | 7% | 7% | 10% | 10% | 11% | 6% | 6% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Shalby insights
64 extracted metrics + investor summaries across FY08–FY26.
Documents
1
Announcement under Regulation 30 (LODR)-Change in Management
12 Sep - Shanay Vikram Shah’s Whole-time Director appointment failed at AGM; he ceased as Additional Director on September 10, 2026. 12 Sep - Shanay Vikram Shah’s Whole-time Director appointment failed at AGM; he ceased as Additional Director on September 10, 2026.
2
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
11 Sep - At September 10, 2026 AGM, resolutions 3 and 4 on Shanay Vikram Shah’s appointment were not passed. 11 Sep - At September 10, 2026 AGM, resolutions 3 and 4 on Shanay Vikram Shah’s appointment were not passed.
3
Board Meeting Intimation for Approving Audited Financial Results (Standalone & Consolidated) For Quarter And Year Ended March 31, 2026, Recommendation Of Dividend, If Any, And Other Business Matters
15h - Board meets May 27, 2026 to approve FY26 audited results and consider dividend. 15h - Board meets May 27, 2026 to approve FY26 audited results and consider dividend.
4
Compliances-Reg.24(A)-Annual Secretarial Compliance
8 May - Shalby filed FY2025-26 annual secretarial compliance report, reporting full compliance and no SEBI actions. 8 May - Shalby filed FY2025-26 annual secretarial compliance report, reporting full compliance and no SEBI actions.
5
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
5 May - Exercise of Employee Stock Options under Shalby Limited Employees Stock Options Scheme-2021 5 May - Exercise of Employee Stock Options under Shalby Limited Employees Stock Options Scheme-2021
Frequently Asked Questions about Shalby
What does Shalby Ltd do?
Shalby Ltd is engaged in healthcare delivery space in India. It operates a chain of multi-specialty hospitals across India. The business of the company is to offer tertiary and quaternary healthcare services to patients in various areas of specialization such as orthopaedics, complex joint replac...
Where is Shalby Ltd (SHALBY) listed?
Shalby Ltd trades as SHALBY on the NSE and under code 540797 on the BSE.
Which sector does Shalby Ltd belong to?
Shalby Ltd is classified under the Healthcare sector, in the Healthcare Services industry.
What is the market capitalisation of Shalby Ltd?
Shalby Ltd has a market capitalisation of ₹1,554 Cr, which places it in the Small Cap band.
What is the PE ratio of Shalby Ltd?
Shalby Ltd trades at a PE ratio of 39.77, on earnings per share of ₹7.22, against a book value of ₹93.11 per share.
What is the 52-week high and low of Shalby Ltd?
Over the last 52 weeks Shalby Ltd has traded between ₹125.82 and ₹274.7.
Does Shalby Ltd pay dividends?
Shalby Ltd has a dividend yield of 0.82%.
What is the Return on Equity (ROE) of Shalby Ltd?
Shalby Ltd reported a return on equity of 3.45%. Its debt-to-equity ratio is 0.59.
Company Information
Shalby Ltd is engaged in healthcare delivery space in India. It operates a chain of multi-specialty hospitals across India. The business of the company is to offer tertiary and quaternary healthcare services to patients in various areas of specialization such as orthopaedics, complex joint replacements, cardiology, neurology, oncology, renal transplantations, etc.[1] The company is the global leader in knee replacement surgery and one of the top Indian hospitals in joint replacement surgery.
Website shalby.org
CEO Dr. Vikram I. Shah
Employees 2,592
Listed 2017-12-15
Face Value ₹ 10
Issued Size 10,80,09,770
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SHALBY.md for Shalby Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.